Abstracts tagged "C-reactive protein (CRP)"

Abstract Number: 1530 • 2018 ACR/ARHP Annual Meeting
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
Oliver Hendricks¹, Stavros Chrysidis², Jens Gerwien³, Chadi Saifan³, Francesco de Leonardis³, Pedro Lopez-Romero³, Jinglin Zhong⁴, Kevin Winthrop⁵ and Josef S. Smolen⁶, ¹King Chr.Xs Rheumatology Hospital, Graasten, Denmark, ²Rheumatology Department Sydvestjysk Sygehus, Esbjerg, Denmark, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Rockville, MD, ⁵Oregon Health Sciences University, Portland, OR, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (BARI) is a selective inhibitor of Janus kinase 1/2, modulating responses to inflammatory cytokines, e.g. IL-6 or IFNs1. During acute inflammation, including those…
Abstract Number: 2619 • 2018 ACR/ARHP Annual Meeting
Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
Lesley Jackson¹, Jeffry Bieber^1,2 and R. Eric Heidel³, ¹Graduate School of Medicine, Department of Internal Medicine, University of Tennessee Medical Center Knoxville, Knoxville, TN, ²UT Rheumatology, Knoxville, TN, ³Graduate School of Medicine, Division of Biostatistics, and Department of Surgery, University of Tennessee Medical Center Knoxville, Knoxville, TN
Background/Purpose: It is well established that psoriatic arthritis is associated with increased cardiovascular disease risk. The use of statins may impart anti-inflammatory effects, possibly through…
Abstract Number: 1954 • 2017 ACR/ARHP Annual Meeting
Association of CRP with BMI in Males and Females
Taik Kim¹, Stephen J. Ganocy², Maria Antonelli³, Douglas Einstadter⁴ and Stanley Ballou¹, ¹Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Department of Medicine/Division of Rheumatology, Case Western Reserve University School of Medicine, MetroHealth Medical Center, Cleveland, OH, ⁴Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: C-reactive Protein (CRP) is an inflammatory marker commonly used to help aid in diagnosis, assess disease activity or monitor response to therapy. It is…
Abstract Number: 2117 • 2017 ACR/ARHP Annual Meeting
C-Reactive Protein and Serum Amyloid a in Sepsis, Acute Appendicitis and Familial Mediterranean Fever
Oguzhan Selvi¹, Serdal Ugurlu², Murat Bolayirli³, Kenan Barut⁴, Sezgin Sahin⁴, Amra Adrovic⁴, Mustafa Akker⁵, Bilgesu Ergezen⁶, Osman Simsek⁷, Ozgur Kasapcopur^4,8 and Huri Ozdogan¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Biochemistry, Istanbul, Turkey, ⁴Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ⁵Department of Anesthesiolog, Sisli Hamidiye Training and Research Hospital, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁷Istanbul University, Cerrahpasa Medical Faculty, Department of General Surgery, Istanbul, Turkey, ⁸Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy
Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent inflammatory attacks. Attacks are accompanied by substantial increase in acute phase reactants such…
Abstract Number: 2212 • 2017 ACR/ARHP Annual Meeting
A Metabolite of C-Reactive Protein, a Marker of Disease Actvity, Is Prognostic of Radiographic Knee OA
Anne C. Bay-Jensen¹, Asger R. Bihlet², Inger Byrjalsen³, Jeppe Andersen⁴, Yi He⁵, Anne Sofie Siebuhr¹, Christian S. Thudium⁶, Bente J. Riis², Claus Christiansen² and Morten Asser Karsdal¹, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Clinical Development, Nordic Bioscience, Herlev, Denmark, ⁵Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁶Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: There are two major needs in clinical DMOAD development: Identifying a population with an active and progressive disease to demonstrate significant improvements by an…
Abstract Number: 2423 • 2017 ACR/ARHP Annual Meeting
Patients with Active Rheumatoid Arthritis but Normal Levels of Acute Phase Proteins Have Altered Regulatory T Cell Function and Rapidly Progress to Biological Therapies
Claire Bradford¹, Shashank Ramakrishnan¹, Andrew Cole², Coziana Ciurtin³, Elizabeth Jury¹ and Jessica Manson⁴, ¹Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ²Centre for Rheumatolofy Research, University College London, London, United Kingdom, ³Rheumatology Department, University College London, London, United Kingdom, ⁴University College London Hospitals NHS Trust, London, United Kingdom
Background/Purpose: An atypical subgroup of patients with seropositive rheumatoid arthritis (RA) was identified with active disease (confirmed by Power Doppler ultrasound (PDUS)) but normal levels…
Abstract Number: 2506 • 2017 ACR/ARHP Annual Meeting
In Ankylosing Spondylitis/Axial Spondyloarthritis Smoking Is Associated with a Dose Related Elevation in CRP, Worse Disease Activity and Worse Quality of Life over One Year
Simon Stebbings¹, Mary Wallace², Andrew A. Harrison³, Nicola Dalbeth⁴, Douglas White⁵, Lisa K. Stamp⁶, Daniel Ching⁷ and John Highton⁸, ¹Dunedin Hospital, Department of Rheumatology, Dunedin, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵Department of Rheumatology, Waikato Clinical School, Hamilton, New Zealand, ⁶University of Otago, Christchurch, New Zealand, ⁷Timaru Medical Specialists Ltd, Timaru, New Zealand, ⁸Dept of Medicine, Univ of Otago Med Sch, Dunedin, New Zealand
Background/Purpose: Analysis of data from several cohort studies of patients with ankylosing spondylitis (AS) /axial spondyloarthritis (AxSpA) have confirmed earlier suggestions that current smokers have…
Abstract Number: 537 • 2017 ACR/ARHP Annual Meeting
No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B Studies
Arthur Kavanaugh¹, Annegret Van der Aa², Corinne Jamoul², Chantal Tasset², Pille Harrison² and René Westhovens³, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Galapagos NV, Mechelen, Belgium, ³Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
Abstract Number: 1352 • 2017 ACR/ARHP Annual Meeting
The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis
Craig Scoville¹, Jessica L. Suboticki², Sheng Zhong³ and Edward C. Keystone⁴, ¹Idaho Falls Arthritis Clinic, Idaho Falls, ID, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) with rheumatoid arthritis (RA) patients (pts), resulting in the…
Abstract Number: 1437 • 2017 ACR/ARHP Annual Meeting
C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
Roy Fleischmann¹, Carol A Connell², Haiyun Fan³ and Sander Strengholt⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Capelle aan den IJssel, Netherlands
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We examined high sensitivity C-reactive protein (hsCRP) levels in relation…
Abstract Number: 1523 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies
Jürgen Braun¹, Joachim Sieper², Robert B.M. Landewé³, Xenofon Baraliakos¹, Corinne Miceli-Richard⁴, Ruvie Martin⁵, Brian Porter⁵, Kunal Gandhi⁵ and Désirée van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, Hôpital Bicêtre, Paris, France, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inhibition of IL-17A with secukinumab is an approved therapy for patients (pts) with AS.1 It has been previously reported that response rates with TNFα…
Abstract Number: 116 • 2017 Pediatric Rheumatology Symposium
Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study
Kathryn Phillippi¹, Thomas Sferra², Nora Singer³ and Elizabeth Brooks⁴, ¹Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, ²Pediatric Gastroenterology, Rainbow Babies and Children's Hospital/Case Medical Center, Cleveland, OH, ³MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio, Cleveland, OH, ⁴Division of Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, Cleveland, OH
Background/Purpose: Inflammatory bowel disease (IBD) is associated with extra-intestinal manifestations, the most common of which is arthralgia/arthritis. 4.1- 15% of patients with inflammatory bowel disease…
Abstract Number: 232 • 2016 ACR/ARHP Annual Meeting
Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study
Talia Igel^1,2, Aaron Garza Romero², Virginia Pike³, Stuart Katz⁴, Binita Shah⁵, Irina Dektiarev⁴, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Monash University School of Medicine, Melbourne, Australia, ²Medicine/Rheumatology, NYU School of Medicine, New York, NY, ³Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁴Medicine/Cardiology, NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Division of Cardiology, New York, NY, ⁶Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: To date, most studies of gout and cardiovascular disease have been cross-sectional or retrospective, and have addressed the outcome of acute coronary syndromes. Less…
Abstract Number: 378 • 2016 ACR/ARHP Annual Meeting
Effects of a Natural Product Containing Specialized Pro-Resolving Mediators in Subjects with OA, RA, or Other Chronic Inflammatory Conditions in a Multi-Clinic Case Series
Annalouise O'Connor¹, Sara Le Brun-Blashka², Kirti Salunkhe², Jyh-Lurn Chang² and John Troup², ¹R&D, Metagenics, Inc., Gig Harbor, WA, ²Metagenics, Inc., Gig Harbor, WA
Background/Purpose: The inflammatory response has an initiation phase and a resolution phase. Ideally, inflammation leads to complete resolution that enables tissue healing and a return…
Abstract Number: 506 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Elevations in CRP with Physical Function and Radiographic Progression over the Long-Term in Patients with Rheumatoid Arthritis
Arthur Kavanaugh¹, Boulos Haraoui², Prashanth Sunkureddi³, Benjamin Wolfe⁴, Li Wang⁴, Jessica Suboticki⁴ and Edward Keystone⁵, ¹University of California San Diego, La Jolla, CA, ²University of Montreal, Montreal, QC, Canada, ³University of Texas Medical Branch, Galveston, TX, ⁴AbbVie Inc., North Chicago, IL, ⁵Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: For patients (pts) with rheumatoid arthritis (RA), quantification of radiographic progression, through measures such as modified total Sharp score (mTSS), is not routinely captured…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].